Legal Proceedings
−Removed: We are involved with various legal matters arising in the ordinary course of business.
+Added: In February 2022, Arbutus and Genevant filed a lawsuit in the U.S.
+Added: District Court for the District of Delaware against Moderna, Inc.
+Added: and a Moderna affiliate seeking damages for infringement of U.S.
+Added: 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of MRNA-1273, Moderna’s vaccine for COVID-19.
+Added: The patents relate to nucleic acid-lipid particles and lipid vesicles, as well as compositions and methods for their use.
+Added: Arbutus and Genevant do not seek an injunction or otherwise seek to impede the sale, manufacture or distribution of MRNA-1273.
+Added: However, the Company seeks fair compensation for Moderna’s use of its patented technology that was developed with great effort and at great expense, without which Moderna’s COVID-19 vaccine would not have been successful.
+Added: We are also involved with various legal matters arising in the ordinary course of business.
We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.
4 unchanged sentences
Certain early work on lipid nanoparticle delivery systems and related inventions was undertaken at the University of British Columbia (“UBC”), as well as by us that was subsequently assigned to UBC.
−Removed: These inventions are licensed to the Company by UBC under a license agreement, initially entered into in 1998 and as amended in 2001, 2006 and 2007.
−Removed: The Company has granted sublicenses under the UBC license to certain third parties, including Alnylam.
−Removed: In November 2014, UBC filed a demand for arbitration against the Company which alleged entitlement to unpaid royalties.
−Removed: In August 2019, the arbitrator issued his decision, awarding UBC $5.9 million, which included interest of approximately $2.6 million.
−Removed: The Company paid the $5.9 million award to UBC in September 2019 and recorded a charge of $6.3 million, consisting of $5.9 million for the award (including interest) and $0.4 million for an estimate of a potential award for costs and attorneys’ fees.
−Removed: An award for costs and attorneys’ fees is still to be determined.
+Added: These inventions are licensed to us by UBC under a license agreement, initially entered into in 1998 and as amended in 2001, 2006 and 2007.
+Added: We granted sublicenses under the UBC license to certain third parties, including Alnylam.
+Added: In November 2014, UBC filed a demand for arbitration against us which alleged entitlement to unpaid royalties.
+Added: In August 2019, the arbitrator issued his decision for the second phase or the arbitration, awarding UBC $5.9 million, which included interest of approximately $2.6 million.
+Added: We paid the $5.9 million award to UBC in September 2019 and paid an additional $0.2 million award for costs and attorneys’ fees in March 2021, and this matter is now fully resolved.
On December 18, 2020, UBC delivered to us a notice of arbitration alleging that under its cross license with us, it is due royalties of $2.0 million plus interest arising from our sale to OMERS of part of our royalty interest on future global net sales of ONPATTRO, currently being sold by Alnylam.
−Removed: We do not believe that any royalties are due to UBC and we intend to vigorously contest UBC’s allegation.
+Added: Oral hearings for this matter are currently scheduled to begin on April 25, 2022.
+Added: We do not believe that any royalties are due to UBC and we intend to vigorously contest UBC’s allegations.
Mine Safety Disclosures
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.